The revenue beat and strong subscriber growth are positive, but the significant swing to negative adjusted EBITDA and YoY revenue decline (-1%) signal near-term profitability pressure. Monitor Q2 2026 guidance for gross margin and patient acquisition cost trends. The stock will likely trade on execution of growth investments translating to revenue acceleration and margin recovery in H2.
Price Chart
Executive Summary
LifeMD reported Q1 2026 revenue of $50.2M, above the $48-49M guidance range and consensus estimate of $48.9M, with subscriber growth of 26% YoY to over 365,000. However, adjusted EBITDA swung to a loss of $4.5M from a profit of $3.7M in prior year, and GAAP net loss widened to $9.6M from $2.4M, as the company front-loaded patient acquisition investments in GLP-1 and women's health. Full-year 2026 guidance was affirmed.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $50.2M vs guidance $48-49M and consensus $48.9M
- Adjusted EBITDA loss of $4.5M vs prior year profit of $3.7M
- Active subscribers up 26% YoY to ~365,000 with record 42,000 net adds
- Gross margin expanded 420 bps to 88%
- GLP-1 new patient revenues grew ~120% QoQ; Women's Health signups up 657% QoQ
- Cash $34.5M, no debt, with $30M undrawn credit facility
- Full year 2026 guidance reaffirmed: revenue $220-230M, adjusted EBITDA $12-17M
Financial Impact
Revenue $50.2M, adjusted EBITDA loss $4.5M, cash $34.5M
Risk Factors
- GLP-1 and women's health adoption may not sustain momentum
- Patient acquisition costs may not decline as planned
- Litigation costs from class action lawsuits may escalate
- Potential dilution from stock-based compensation or future capital needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-021520 |
| Document: form8-k.htm | 0001493152-26-021520 |
| Document: 0001493152-26-021520-index-headers.html | 0001493152-26-021520 |
| Document: 0001493152-26-021520-index.html | 0001493152-26-021520 |
| Document: 0001493152-26-021520.txt | 0001493152-26-021520 |
| 8-K Data (Synthetic) | 0001493152-26-021520 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers